|45.15||+2.91||+6.89%||Vol 3.20M||1Y Perf -67.13%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||-0.28 -0.62%|
|Target Price||98.40||Analyst Rating||Strong Buy 1.25|
|Potential %||117.94||Finscreener Ranking||★★★+ 50.92|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★ 46.08|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★+ 47.57|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||9.94||Earnings Rating||Buy|
|Market Cap||7.94B||Earnings Date||27th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Jul 2022|
|Estimated EPS Next Report||-1.08|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.45M|
|Avg. Monthly Volume||2.14M|
|Avg. Quarterly Volume||2.12M|
Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 45.15 per share at the end of the most recent trading day (a 6.89% change compared to the prior day closing price) with a volume of 3.20M shares and market capitalization of 7.94B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.
The one-year performance of Exact Sciences Corporation stock is -67.13%, while year-to-date (YTD) performance is -41.99%. EXAS stock has a five-year performance of 27.15%. Its 52-week range is between 35.34 and 133.99, which gives EXAS stock a 52-week price range ratio of 9.94%
Exact Sciences Corporation currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.23, a price-to-sale (PS) ratio of 3.54, a price to cashflow ratio of 364.30, a PEG ratio of 2.32, a ROA of -11.60%, a ROC of -12.57% and a ROE of -22.24%. The company’s profit margin is -40.11%, its EBITDA margin is -29.90%, and its revenue ttm is $1.85 Billion , which makes it $10.52 revenue per share.
Of the last four earnings reports from Exact Sciences Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Exact Sciences Corporation’s next earnings report date is 27th Jul 2022.
The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.25), with a target price of $98.4, which is +117.94% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exact Sciences Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.90, ATR14 : 3.43, CCI20 : 0.51, Chaikin Money Flow : -0.08, MACD : -3.44, Money Flow Index : 51.25, ROC : -6.13, RSI : 49.57, STOCH (14,3) : 62.17, STOCH RSI : 1.00, UO : 55.19, Williams %R : -37.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: James E. Doyle (Option Excercise at a value of $214 760), James E. Doyle (Sold 2 640 shares of value $293 489 ), Jeffrey T. Elliott (Option Excercise at a value of $311 127), Jeffrey T. Elliott (Sold 45 807 shares of value $4 837 927 ), Katherine S. Zanotti (Sold 1 381 shares of value $153 439 ), Kevin T. Conroy (Option Excercise at a value of $5 851 572), Kevin T. Conroy (Sold 114 628 shares of value $10 878 114 ), Sarah Condella (Option Excercise at a value of $318 020), Sarah Condella (Sold 20 716 shares of value $1 549 462 ), Scott D. Coward (Option Excercise at a value of $622 254), Scott D. Coward (Sold 9 756 shares of value $741 613 )
Tue, 25 Jan 2022 20:26 GMT Exact Sciences: Could Decline More in 2022- TipRanks. All rights reserved.
Thu, 20 Jan 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Encompass Health (EHC)- TipRanks. All rights reserved.
Thu, 20 Jan 2022 01:25 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), UnitedHealth (UNH)- TipRanks. All rights reserved.
Tue, 11 Jan 2022 18:20 GMT Exact Sciences (EXAS) Gets a Buy Rating from Leerink Partners- TipRanks. All rights reserved.
Tue, 11 Jan 2022 18:15 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and NanoString Tech (NSTG)- TipRanks. All rights reserved.
Tue, 11 Jan 2022 15:26 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.